Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?

Critical Care Medicine

Volumn 36, Issue 4, 2008, Pages 1311-1322

  Ospina Tascón, Gustavo A ^a   Büchele, Gustavo Luiz ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Critically ill; Mortality; Outcome

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DATA EXTRACTION; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION RETRIEVAL; INTENSIVE CARE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL;

EID: 41649116334     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318168ea3e     Document Type: Article

References (98)

1. Sackett DL, Rosenberg WMC, Gray JAM, et al: Evidence-based medicine: What it is and what it isn't. BMJ 1996; 312:71-72
2. Druss B: Evidence based medicine: Does it make a difference? Use wisely. BMJ 2005; 330:92
3. Vincent JL: Evidence-based medicine in the ICU: Important advances and limitations. Chest 2004; 126:592-600
4. Vincent JL: Which therapeutic interventions in critical care medicine have been shown to reduce mortality in prospective, randomized, clinical trials? Crit Care Med 2000; 28:1616-1620
5. Ferreira F, Vincent JL, Brun-Buisson C, et al: Doctors' perceptions of the effects of interventions tested in prospective, randomised, controlled, clinical trials: Results of a survey of ICU physicians. Intensive Care Med 2001; 27:548-554
6. Sandham JD, Hull RD, Brant RF, et al: A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5-14
7. Richard C, Warszawski J, Anguel N, et al: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2003; 290:2713-2720
8. Wheeler AP, Bernard GR, Thompson BT, et al: Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224
9. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa [activated] for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
10. Bone RC, Fisher CJJ, Clemmer TP, et al: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
11. Hayes MA, Timmins AC, Yau EH, et al: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-1722
12. Amato MB, Barbas CS, Medeiro DM, et al: Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347-354
13. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276:637-639
14. The ARDS Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
15. Villar J, Kacmarek RM, Perez-Mendez L, et al: A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: A randomized, controlled trial. Crit Care Med 2006; 34:1311-1318
16. Esteban A, Alia I, Gordo F, et al: Prospective randomized trial comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS. For the Spanish Lung Failure Collaborative Group. Chest 2000; 117:1690-1696
17. Dominioni L, Dionigi R, Zanello M, et al: Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126:236-240
18. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
19. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
20. Gutierrez G, Palizas F, Doglio G, et al: Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339:195-199
21. Laurent I, Adrie C, Vinsonneau C, et al: High-volume hemofiltration after out-of-hospital cardiac arrest: A randomized study. J Am Coll Cardiol 2005; 46:432-437
22. Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 2000; 132:621-630
23. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334:1697-1702
24. Lopez A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
25. Esteban A, Frutos-Vivar F, Ferguson ND, et al: Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004; 350:2452-2460
26. Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60:1154-1163
27. Takala J, Ruokonen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792
28. Sloan EP, Koenigsberg M, Gens D, et al: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857-1864
29. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659-665
30. Hentrich M, Fehnle K, Ostermann H, et al: IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial. Crit Care Med 2006; 34:1319-1325
31. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336:912-918
32. Calandra T, Glauser MP, Schellekens J, et al: Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 1988; 158:312-319
33. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324:429-436
34. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23:994-1006
35. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:1-5
36. Angus DC, Birmingham MC, Balk RA, et al: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723-1730
37. Albertson TE, Panacek EA, MacArthur RD, et al: Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31:419-427
38. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273:934-941
39. Cohen J, Carlet J, INTERSEPT Study Group: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24:1431-1440
40. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351:929-933
41. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
42. Abraham E, Laterre PF, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-510
43. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
44. Fisher CJ, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-1843
45. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1124
46. Dhainaut JF, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26:1963-1971
47. Opal S, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32:332-341
48. Fein AM, Bernard GR, Criner GJ, et al: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). JAMA 1997; 277:482-487
49. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
50. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
51. Abraham E, Naum C, Bandi V, et al: Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31:718-728
52. Zeiher BG, Steingrub J, Laterre PF, et al: LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005; 33:1741-1748
53. Gattinoni L, Tognoni G, Pesenti A, et al: Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001; 345:568-573
54. Guerin C, Gaillard S, Lemasson S, et al: Effects of systematic prone positioning in hypoxemic acute respiratory failure: A randomized controlled trial. JAMA 2004; 292:2379-2387
55. Mancebo J, Fernandez R, Blanch L, et al: A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173:1233-1239
56. Brochard L, Roudot-Thoraval F, Roupie E, et al: Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trail Group on Tidal Volume reduction in ARDS. Am J Respir Crit Care Med 1998; 158:1831-1838
57. Stewart TE, Meade MO, Cook DJ, et al: Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. N Engl J Med 1998; 338:355-361
58. Brower RG, Lanken PN, Macintyre N, et al: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327-336
59. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
60. Anzueto A, Baughmann RP, Guntupalli KK, et al: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334:1417-1421
61. Bone RC, Maunder R, Slotman G, et al: An early test of survival in patients with the adult respiratory distress syndrome: The PaO2/FlO2 ratio and its differential response to conventional therapy. Chest 1989; 96:849-851
62. The ARDS Network: Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2000; 283:1995-2002
63. Vincent JL, Brase R, Dhainaut JF, et al: A multicenter, double blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001; 27:1578-1583
64. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome Crit Care Med 2002; 30:1-6
65. Zeiher BG, Artigas A, Vincent JL, et al: Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Crit Care Med 2004; 32:1695-1702
66. Steinberg KP, Hudson LD, Goodman RB, et al: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684
67. Root RK, Lodato RF, Patrick W, et al: Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-373
68. Gastinne H, Wolff M, Delatour F, et al: A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. N Engl J Med 1992; 326:594-599
69. Caparros T, Lopez J, Grau T: Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet: The effect on nosocomial infections and outcome. JPEN J Parenter Enteral Nutr 2001; 25:299-308
70. Bouman CS, Oudemans-van Straaten HM, Tijssen JG, et al: Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med 2002; 30:2205-2211
71. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333:1025-1032
72. Takala J, Meier-Hellmann A, Eddleston J, et al: Effect of dopexamine on outcome after major abdominal surgery: A prospective, randomized, controlled multicenter study. European Multicenter Study Group on Dopexamine in Major Abdominal Surgery. Crit Care Med 2000; 28:3417-3423
73. Bilgin YM, van de Watering LM, Eijsman L, et al: Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109:2755-2760
74. van Hilten JA, van de Watering LM, van Bockel JH, et al: Effects of transfusion with red cells filtered to remove leucocytes: Randomised controlled trial in patients undergoing major surgery. BMJ 2004; 328:1281
75. Harvey S, Harrison DA, Singer M, et al: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): A randomised controlled trial. Lancet 2005; 366:472-477
76. Chastre J, Wolff M, Fagon JY, et al: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290:2588-2598
77. Finfer S, Bellomo R, Boyce N, et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256
78. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
79. Schulz KF, Chalmers I, Grimes DA, et al: Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994; 272:125-128
80. Schulz KF, Chalmers I, Hayes RJ, et al: Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412
81. Halpern SD, Karlawish JH, Berlin JA: The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288:358-362
82. Huwiler-Muntener K, Juni P, Junker C, et al: Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002; 287:2801-2804
83. Lauer MS, Blackstone EH, Young JB, et al: Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol 1999; 34:618-620
84. Altman DG: Statistics and ethics in medical research: III How large a sample? BMJ 1980; 281:1336-1338
85. Sprung: Paper presented at: Annual Meeting of the European Society of Intensive Care Medicine, September 2006; Barcelona
86. Friedrich JO, Adhikari NK, Meade MO: Drotrecogin alfa (activated): Does current evidence support treatment for any patients with severe sepsis? Crit Care 2006; 10:145
87. Wong SS, Wilczynski NL, Haynes RB: Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 2006; 94:451-455
88. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-1291
89. Meduri GU, Headley AS, Golden E, et al: Effect of prolonged methylprednisolone therapy in unresolving respiratory distress syndrome: A randomized controlled trial. JAMA 1998; 280:159-165
90. Nava S, Ambrosino N, Clini E, et al: Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease: A randomized, controlled trial. Ann Intern Med 1998; 128:721-728
91. Darenberg J, Ihendyane N, Sjolin J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340
92. Gay PC, Hess DR, Hill NS: Noninvasive proportional assist ventilation for acute respiratory insufficiency. Comparison with pressure support ventilation. Am J Respir Crit Care Med 2001; 164:1606-1611
93. Dellinger RP, Carlet JM, Masur H, et al: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
94. Taylor RW, Zimmerman JL, Dellinger RP, et al: Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 2004; 291:1603-1609
95. Kacmarek RM, Wiedemann HP, Lavin PT, et al: Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173:882-889
96. Cook D, Heyland D, Marshall J: On the need for observational studies to design and interpret randomized trials in ICU patients: A case study in stress ulcer prophylaxis. Intensive Care Med 2001; 27:347-354
97. Sakr Y, Reinhart K, Vincent JL, et al: Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34:589-597
98. Smith GC, Pell JP: Parachute use to prevent death and major trauma related to gravitational challenge: Systematic review of randomised controlled trials. BMJ 2003; 327:1459-1461